Chronic myelogenous leukaemia - New therapeutic principles

Journal of Internal Medicine

Volumn 250, Issue 1, 2001, Pages 3-9

  O'Dwyer, Michael E ^a   Druker, Brian J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

BCR ABL; Chronic myelogenous leukaemia; Signal transduction; STI571; Therapy; Tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; CPG 57148 B; HYDROXYUREA; IMATINIB; INTERFERON; PROTEIN TYROSINE KINASE; STI 1571;

BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 0035724240     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2001.00823.x     Document Type: Review

References (39)

1. Chronic myeloid leukemia
2. Chronic myelogenous leukemia: A review
3. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
4. A minute chromosome in human chronic granulocytic leukemia
5. Fused transcript of ABL and BCR genes in chronic myelogenous leukaemia
6. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products
7. Induction of chronic myelogenous leukemia in mice by the P210BCR/ABL gene of the Philadelphia chromosome
8. Acute leukaemia in BCR/ABL transgenic mice
9. Chronic myelogenous leukemia: Biology and therapy
10. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission
11. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
12. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
13. Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients
14. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cyto-reduction for the treatment of malignant and nonmalignant hematologic diseases
15. Improving availability and safety of unrelated donor transplants
16. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient
17. Leukocyte interferon-induced myeloid cyto-reduction in chronic myelogenous leukaemia
18. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
19. UK Medical Research Council randomised, multicentre trial of interferon- alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response
20. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase
21. Interferon alfa versus chemotherapy for chronic myeloid leukemia. A meta-analysis of seven randomized trials
22. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
23. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure
24. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors
25. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
26. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells
27. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
28. Favorable therapeutic index of a p210 (BCR-ABL) - Specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors
29. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
30. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190, 000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
31. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
32. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
33. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogenous leukemia in blast crisis
34. Efficacy of STI571, an ABL tyrosine kinase inhibitor, in conjunction with other antileukemic agents against BCR-ABL-positive cells
35. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
36. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
37. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
38. Trial of IFN or STI571 before proceeding to allografting for CML?